Objective. To analyse and report the costs and effects of etanercept therapy in patients with JIA.
Introduction
JIA is one of the most common autoimmune diseases in childhood, prevalence is about 1 in 1000 children [1, 2] . JIA can result in irreversible changes in cartilage and bone and long-term functional impairment. Chronic diseases such as JIA usually have high economic impact, as patients will suffer from the disease throughout their whole life. More than 50% of children with JIA enter adulthood with ongoing active disease [3, 4] . Bernatsky et al. [5] analysed the direct medical costs for children with JIA compared with controls. They concluded that the economic impact of JIA is substantial, and that a higher active joint count is independently associated with greater costs. The relationship between active disease and increase in costs was also seen in studies by Minden et al. [6, 7] .
Current guidelines require patients with a polyarticular course to be treated with DMARDs, mostly MTX, if required accompanied by IA or systemic glucocorticoids [4, 8] . Since its introduction, etanercept has become an important treatment for patients with JIA refractory to synthetic DMARDs. Several studies have shown an impressive decline in disease activity expressed by the JIA core set of response variables during treatment with etanercept [915] . Etanercept is a high-cost drug compared with more traditional medication, such as MTX. On the other side, suppressing disease activity effectively early in the disease course might prevent pain and disability and subsequently reduce costs in the long term [16] . Therefore, it is important to have more insight into the costs and effects (i.e. utility) of etanercept in JIA. Our aim was to analyse and report the costs and effects of etanercept therapy in patients with JIA.
Methods
Patients and data from the Arthritis and Biologicals in Children-register In the Netherlands, JIA patients are eligible for treatment with etanercept if the disease has a polyarticular course and the response to the maximum (tolerated) dose of MTX is not sufficient. All Dutch JIA patients younger than 18 years treated with etanercept are included in the national Arthritis and Biologicals in Children (ABC) register to evaluate long-term effectiveness and safety of etanercept and other biologic DMARDs [14, 17] .
For all included patients data on patient and disease characteristics, including gender, date of birth, date of JIA onset, JIA subtype, medical history, previous medication and data on the use of etanercept such as dose, frequency, use of concomitant drugs and (serious) adverse events are collected in the ABC register. Also, disease activity is evaluated and entered into the register at the start of treatment, after 3 months, 15 months and every year thereafter. The outcome measures used to assess disease activity consisted of the following set of six response variables of the JIA core set: (i) overall assessment of disease activity by the physician through the visual analogue scale (VAS) (range 0100 mm, 0 best score); (ii) childhood HAQ (CHAQ) (range 03, 0 best score) by the patient or parent; (iii) overall assessment of well-being by the patient or parent through the VAS (range 0100 mm, 0 best score); (iv) number of active joints (joints with swelling not caused by deformity, or joints with limited motion and with pain, tenderness or both); (v) number of joints with limited motion; and (vi) a laboratory marker of inflammation, ESR [18] .
We prospectively collected additional data on the Health Utilities Index Mark 3 (HUI3) from patients in the register from 2003 until 2006 [19] . Seven of the nine Dutch paediatric rheumatology centres agreed to participate in this add-on study. Parents of eligible patients were asked to complete the HUI3 at the start and after 3, 15 and 27 months of treatment.
The protocol was approved by the Medical Ethical Committee of Erasmus MC, Rotterdam and local medical ethics committee approval was given in every participating centre. Written informed consent was obtained, and the study was conducted in accordance with the Declaration of Helsinki.
Cost and effect analysis
We collected data on costs in the 12 months before the start of etanercept treatment and in the 27 months thereafter. From a social perspective, there are several costs that should be taken into account. Direct medical costs involve expenses incurred directly pertaining to medical care, e.g. costs concerning medication, diagnostic procedures and hospitalization. Direct non-medical costs are primarily related to out-of-pocket expenses incurred by the patient due to illness (e.g. travel and time expenses; these expenses are related to the disease, but are not medical expenses). We collected all direct medical costs from paper and electronic patients' files and completed by treating physician inquiry. In addition, parents were asked to fill out cost diaries during etanercept therapy, to estimate direct non-medical costs. However, parents were reluctant to fill out these dairies, and due to the bad response (89% missing) we decided to report only the direct medical costs.
Prices for all hospital-related costs were based on real prices from the coordinating centre (Erasmus MC Sophia Children's Hospital), which are representative of all participating hospitals. Costs for medication were retrieved from the Pharmacotherapeutic Compass provided by the Dutch Board of Health Insurances (CVZ) [20] . We calculated costs for all drugs with the exact dose of medication and administration period as reported in the patients' files. The base year was 2008 for all costs; costs retrieved from other years were converted to 2008 euros using the general Dutch price index rate (www.cbs.nl).
To evaluate the effect of etanercept we used the HUI3. The HUI3 is a preference-based health-related quality of life (HRQoL) measure that includes a classification system that indicates the level of impairment in eight domains (attributes) based on information retrieved by a 15-item parent questionnaire. These eight single attributes in the HUI3 are vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain, each with five or six levels representing the range of functioning from not (1) to severely impaired (5 or 6). The parents of the JIA patients were asked to complete the HUI3 at the start of etanercept, and after 3, 15 and 27 months of therapy. In our study, we used the proxy assessment since children are considered to be unable to value health states [21] .
We applied the single-and multi-attribute utility formulas suggested by Feeny et al. [22] for estimating single-and multi-attribute utilities. The latter is scored on a scale from 0 (dead) to 1 (perfect health). The utilities reflect the value of HRQoL measured from the social perspective.
Statistical analysis
All outcomes including means, medians, S.E.M.s and inter-quartile range (IQR) were calculated using statistical software SPSS 15.0.1. (SPSS Inc., Chicago, IL, USA). We compared the characteristics of the 49 patients included in this study with those of the 146 patients that were included in the ABC register at the end of 2006 using the two-sample t-test and chi-squared test. We tested whether any significant changes were found comparing outcomes of HUI3 questionnaires and disease activity response variables over time using linear mixed models to account for the correlations between the repeated measurements. We inserted disease duration at start of etanercept as a continuous covariance and onset JIA subtype (systemic and non-systemic JIA) as categorical covariance for all models. Intercept was set as random variable, time of questionnaire assessment, disease duration and JIA subtype as fixed variables. Compound symmetry was defined as covariance structure. P < 0.05 was considered to be statistically significant.
Results

Patient and disease characteristics
During the study period, 53 JIA patients completed the HUI3 during treatment with etanercept, of which 49 patients continued etanercept treatment for at least 27 months. Four (three systemic and one polyarticular RF-positive JIA) patients discontinued etanercept because of inefficacy after a median use of 14.3 months (IQR 3.326.7). Of the 49 patients included in this study, the median age at start of etanercept was 11.6 years with median disease duration of 3.6 years. Etanercept was given in the dose 0.4 mg/kg twice weekly or 0.8 mg/kg once weekly [23] . History of anti-rheumatic drug use and concomitant drug use at start of etanercept are shown in Table 1 . The patient and disease characteristics (Table 1) are representative for the 146 patients that were included in the ABC register at the end of 2006 [14] . No significant differences between groups were found in disease duration before start of etanercept (P = 0.16) or JIA subtype being systemic or non-systemic (P = 0.56).
Cost and effect analysis
Total direct medical costs before start of etanercept therapy were 3720 euros per patient per year as shown in Table 2 . After start, calculated over a 2.25-year period, mean costs are 12 478 euros per patient per year (Table 2) . More than three-quarters of these costs were direct etanercept costs. Most other direct medical costs were reduced compared with the period before start of etanercept: 43% reduction in the period 315 months after the start of etanercept and 55% in the period 1527 months after start. The number of visits to the paediatric rheumatologist and other specialist are distinctly lower during etanercept use and also hospitalization costs decrease substantially over time. Costs for DEXA scans were high in the first 3 months after start of etanercept due to study protocol.
The outcomes of both the HUI3 and the disease activity response variables of the JIA core set are shown in Table 3 . The gain in utility over the study period is 0.25 on a score from 0 to 1, from start (0.53) to 27 months (0.78) of etanercept treatment. As we previously showed, the HUI3 improves on all utility functions impaired by JIA, but seems less sensitive for changes on emotions as compared with the CHAQ and Child Health questionnaire [19] .
Discussion
If severe JIA is not treated effectively it can lead to irreversible damage to the joints, long-term disability and other serious problems such as growth inhibition. As previously reported, etanercept not only suppresses disease activity in JIA patients, but also improves HRQoL [14, 19] . However, it comes with high costs. Results from the current cost analysis show that the total direct cost per year before start of etanercept therapy was 3720 euros per patient, and 12 478 euros per patient per year after start of etanercept. Our study indicated that etanercept itself accounts for more than three-quarters of the direct medical costs, when JIA patients are treated with this drug. Other direct medical costs decreased during etanercept therapy by 55% after 27 months of etanercept therapy, although this was not seen yet in the first 3 months of HRQoL measures provide important information on the burden of JIA and the improvements offered by new treatments [16] . Although we previously published outcomes on the HUI3 from 53 JIA patients in the ABC register, we shortly described results from 49 of these patients again to provide crucial information on the quality of the treatment effect [19] . The 49 patients, who used etanercept for at least 27 months, showed an impressive utility gain of 0.25 (from 0.53 to 0.78 on a scale from 0 to 1). All domains impaired by JIA improved during etanercept. It was encouraging that we found not only a utility improvement after 3 months and 15 months of treatment, but also an additional strong improvement after 27 months.
Thornton et al. [24] demonstrated in their study in JIA patients that visits to the paediatric rheumatologist account for the largest component of the total costs during the first year after diagnosis. Being able to lower these costs, as demonstrated in our study, is therefore profitable. Other studies have reported on the costs of etanercept. A costutility analysis was undertaken as part of the manufacturer's submission. For a patient started on etanercept rather than placebo, the incremental benefit estimated per patient was 1.74 quality-adjusted life years (QALYs). Cost per QALY was 16 082 British pounds (range 390034 000 pounds) [25] . However, their model was based on a model for RA and contained a large number of strong assumptions that made accuracy of the estimate questionable. In addition, in daily practice, paediatric rheumatologists make choices between etanercept and conventional drugs, not placebo. Recently, a study from Canada reported incremental costs of biologic DMARDs in JIA, including etanercept, compared with MTX treatment as estimated by economic models. The additional costs (direct and indirect) for etanercept were estimated at 26 061 Canadian dollars (95% CI 17 070, 41 834) for patients who had an improvement of 30% in at least three variables of the JIA core set and worsening in not more than one variable by >30% (ACR Pediatric 30) at 1 year [26] . Authors did not consider HRQoL data for their analysis, although these do exist for etanercept and abatacept, and estimation is not very precise as shown by the quite wide CI [19, 27] . A study from Finland retrospectively collected costs from 31 JIA patients from medical records and by interviewing parents before and during etanercept treatment [28] . They also showed an increase in direct medical costs due to use of etanercept, compared with the prevailing treatment, but also showed a decrease in indirect costs of 50%. However, they did not compare costs of therapy with an effect such as treatment response or HRQoL. Our study represents real-life data over a longer period of time, includes results from the HUI3 and treatment response data, and no assumptions were made.
Patients in our study already had relatively high direct medical costs before start of etanercept compared with costs from patients reported in other studies on JIA [57] .
These findings suggests what also has been reported in literature; that the severity of JIA is related to the height of medical costs, since patients in our study were refractory to therapy previous to etanercept therapy and had high disease activity before start of etanercept. Our study had some limitations. First of all, we only captured direct medical costs. Although we did not capture indirect costs and direct non-medical costs, we expect that these costs are minimal in comparison with the direct medical costs [7, 16] . Secondly, costs were collected from patients' files and electronic records rather than through cost questionnaires obtained from parents. Therefore, it was not possible to evaluate indirect costs. However, parents were reluctant to give financial information and the information on direct medical costs retrieved from the files was very complete and accurate. Thirdly, ideally costs and utilities would be compared with a control group. However, since etanercept has proven to be very successful in JIA patients refractory to synthetic DMARDs including MTX, this would not be ethical. Fourth, the current study was done in Dutch JIA patients. Therapeutic strategies may vary from other countries and also costs can vary.
In general, many studies reported on the effectiveness and safety of new drugs in treatment of JIA. Especially the introduction of biologic DMARDs have let to substantially higher drug costs [7] . However, these costs should be compared with the reduction of pain and prevention of irreversible damage to the joints and lifelong disabilities. Etanercept and concomitant medication may even be discontinued successfully in some JIA patients after reaching remission, which would reduce costs [29] . The results from our cost analysis show that although etanercept is expensive, it is an important intervention for JIA patients previously refractory to treatment, since it can establish great utility gain in a short period of time, with further improvement in the years thereafter. These results indicate that medical costs and costs related to long-time disability can be prevented in the future.
Rheumatology key messages
. On average costs of etanercept therapy per patient per year were 10 478 euros. . Costs concerning, among others, hospitalization, outpatient clinic visits and concomitant medication decreased during etanercept therapy. . Although etanercept is expensive, the major utility gain justifies the costs. 
